Statins are linked to lower glaucoma risk in a large real-world cohort
A cholesterol drug may have an eye benefit that reaches beyond lipid control. In a large observational analysis published in the British Journal of Ophthalmology, statin use was associated with a lower risk of developing open-angle glaucoma and a reduced likelihood of needing glaucoma procedures over time.
Glaucoma remains one of the most consequential chronic eye diseases in clinical practice because the damage is often silent until vision has already been lost. The condition injures the optic nerve, and once that injury accumulates, it cannot be reversed. Standard treatment still centers on lowering intraocular pressure, yet many patients continue to progress even when pressure is brought into target range.
The findings add to a growing body of work suggesting that glaucoma is not governed by pressure alone. Vascular biology, inflammation, and optic nerve resilience all appear to influence who develops disease and who worsens despite treatment.
Risk reduction emerged over years of follow-up
Investigators evaluated medical records from about 210,000 adults older than 40 years who had used statins and matched them against a comparison group that had never used statins. The cohort was followed for two time points, creating a view of whether any association persisted rather than fading with time.
At 5 years, statin users had a 15% lower risk of developing open-angle glaucoma. At 10 years, the reduction was 10%. Those numbers do not prove causation, but they do point to a sustained relationship between statin exposure and glaucoma incidence in a large clinical dataset.
A one-sentence signal stands out: the association did not disappear with longer observation. Instead, it remained measurable, suggesting a chronic biological effect rather than a transient statistical fluctuation.
For clinicians, that matters because glaucoma prevention is most valuable before structural optic nerve loss appears on exam or visual field testing. Any medication already widely prescribed for cardiovascular risk that also corresponds with lower glaucoma incidence deserves careful scrutiny.
Fewer patients needed glaucoma procedures
The study reached beyond diagnosis alone and examined treatment escalation among people already living with glaucoma. Statin use was associated with a lower likelihood of needing incisional glaucoma surgery, minimally invasive glaucoma surgery (MIGS), and selective laser trabeculoplasty (SLT).
After 5 years, the risk reductions were 36% for incisional glaucoma surgery, 55% for MIGS, and 60% for SLT. At 10 years, the corresponding reductions were 32%, 46%, and 51%.
Those are clinically meaningful procedure-related outcomes because surgery usually enters the conversation when medications and laser therapy are not enough to protect the optic nerve. A lower rate of surgical escalation suggests either slower disease progression, better pressure control, or both. It may also reflect biologic effects outside the classic pressure-lowering pathway.
Why a lipid drug might matter in the optic nerve
Several mechanisms could explain the association. Statins are best known for lowering cholesterol, but they also influence endothelial function, inflammation, and perhaps the microscopic pathways that govern aqueous humor drainage from the eye. If outflow resistance decreases even modestly, intraocular pressure could become easier to control.
The optic nerve may also benefit directly. Experimental and clinical observations have suggested that statins may exert neuroprotective effects, which would be especially relevant in a disease where retinal ganglion cell death drives permanent vision loss. That possibility is attractive because it addresses a weakness in current glaucoma care: nearly all standard therapies focus on pressure, while the disease likely involves several damaging processes at once.
This is where the study becomes more interesting than a routine association between a common drug and a common diagnosis. If statins reduce inflammation or improve microvascular function around the optic nerve head, they could help tissues tolerate the same pressure environment that would otherwise cause damage.
Expert commentary points to promise, not a practice change
Robert N. Weinreb, MD, the study’s lead author, said that lowering the risk of open-angle glaucoma reduces the likelihood of vision loss. He also stressed that statins should be viewed as complementary to standard intraocular pressure-lowering treatment if future prospective work confirms the association. Statins are not meant to replace established glaucoma therapy.
Benjamin Bert, MD, who was not involved in the research, described the results as interesting because they suggest statins may lower the risk of glaucoma while also reducing escalation of treatment in patients who already have the disease. He pointed to the possibility of a broader neuroprotective effect and noted that some forms of glaucoma continue to progress despite adequate pressure control.
Daniel Liebman, MD, MBA, offered a similar reading. He called the analysis large and well designed, while also emphasizing a core limitation: it is not a randomized controlled trial. Without randomization, the results cannot prove that statins themselves caused the lower glaucoma risk.
That limitation is not a footnote. Patients who take statins may differ from nonusers in ways that also influence eye health, including access to care, comorbidity burden, and the frequency of medical follow-up.
What this means for glaucoma care now
The practical message is restrained. These data do not justify starting a statin solely to prevent glaucoma. They do, however, strengthen the case for studying statins as part of a broader strategy to protect the optic nerve.
For patients who already need a statin for cardiovascular indications, the possibility of an additional ocular benefit is welcome. For glaucoma specialists, the study reinforces a familiar point: pressure lowering remains central, but it may not be the whole story. Disease biology likely extends into inflammatory and neurodegenerative pathways that current treatments only partially address.
Research into those pathways could eventually identify a drug that protects retinal ganglion cells more directly or improves outflow in a targeted way. For now, the key unanswered issue is whether the association will hold in prospective randomized trials and whether any optic nerve benefit can be separated cleanly from the cardiovascular and metabolic profile of statin users.
Until then, statins belong in the category of plausible adjuncts, not replacements. The next step is evidence that can separate correlation from treatment effect and determine whether the optic nerve benefit survives when the study design is no longer observational.